{"version":"1.0","provider_name":"Bloom Burton","provider_url":"https:\/\/www.bloomburton.com\/wordpress","author_name":"Brian Bloom","author_url":"https:\/\/www.bloomburton.com\/wordpress\/author\/bbloom\/","title":"Looking Inside the Biotech Black Box (Part 1) - Bloom Burton","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"FKGuAvc1aC\"><a href=\"https:\/\/www.bloomburton.com\/wordpress\/looking-inside-biotech-black-box-part-1\/\">Looking Inside the Biotech Black Box (Part 1)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.bloomburton.com\/wordpress\/looking-inside-biotech-black-box-part-1\/embed\/#?secret=FKGuAvc1aC\" width=\"600\" height=\"338\" title=\"&#8220;Looking Inside the Biotech Black Box (Part 1)&#8221; &#8212; Bloom Burton\" data-secret=\"FKGuAvc1aC\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.bloomburton.com\/wordpress\/wordpress\/content\/uploads\/Part_1_BiotechBlackBoxes_Final.png","thumbnail_width":517,"thumbnail_height":276,"description":"Introduction &nbsp; In mid-2011 I started a 26-part blog series titled \u2018Valuation &amp; Other Biotech Mysteries\u2019. Some aspects of the valuation blogs have not changed, such as NPV calculations. Other aspects have changed substantially \u2013 and will continue to change, such as the state of capital markets, investor interest in biotech, reimbursement problems, and the [&hellip;]"}